anthonyyazdaniml/gliner-biomed-balanced-curated-corpus huggingface dataset:
PURPOSE:To obtain a composition for the oral cavity, containing a water- insoluble drug effect agent absorbing on mucous membranes and effectively acting thereon, a hydrophilic surfactant and ethanol and having high preventive and treating effects on periodontosis and excellent in feeling of use. CONSTITUTION:A composition for the oral cavity containing &lt;= 20 wt.% water- insoluble drug effect agent (e.g. vitamin E), a hydrophilic surfactant (e.g. DL- pyrrolidonecarboxylate of N&lt;alpha&gt;-cocoyl-L-arginine ethyl ester) in an amount of &lt;=2 times based on a water-insoluble ingredient such as perfume and ethanol in an amount of &gt;= 2.5 times based on the water-insoluble ingredient and &gt;=50 wt.% based on the whole composition. Furthermore, an optional ingredient such as a sweetener, a wetting agent, fats and oils, a water-soluble drug effect agent or a coloring matter is suitably blended and prepared according to a conventional method to afford the objective substance. The composition can be applied as a mouthwash, a liquid dentifrice, a gargle agent, etc.
NEW MATERIAL:The benzo-heterocyclic compound of formula I [R is halogen or group of formula II (R&lt;2&gt; is H or lower alkyl); R&lt;1&gt; is OH or lower alkoxy; X is halogen] or its salt. EXAMPLE:6,7-Difluoro-1-(4-methoxyphenyl)-1,4-dihydro-4-oxo-qui-noline- 3-carboxy-lic acid. USE:It has remarkable antibacterial activity against Gram-negative bacteria and Gram- positive bacteria such as Pseudomonas aeruginosa, anaerobic bacteria, etc., and is useful as a remedy for diseases caused by the above bacteria. It can be used also as an antibacterial agent having low toxicity and weak side effect and usable also as an external disinfectant and sterilizer for medical tools. etc. PREPARATION:The compound of formula Ia which is one of the compound of formula I can be prepared by hydrolyzing the compound of formula III (X&lt;1&gt; is halogen; R&lt;4&gt; is lower alkyl) by conventional method. If necessary, the product is converted to the compound of formula Ib which is another form of the compound of formula I by reacting with the compound of formula 11 in an inert solvent.
PROBLEM TO BE SOLVED: To obtain the subject compound having inhibitory effect on 5- hydroxytryptamine, thus useful as a therapeutic agent for various diseases including parkinson&#39;s disease, by transforming paroxetine or the like into the corresponding hydrochloride. SOLUTION: First, Paroxetine or a lower alkanoic acid salt thereof is dissolved in an appropriate solvent, and at least an equivalent of hydrogen chloride gas or the like is then introduced into the resultant solution followed by conducting a reaction pref. at -20 to 50 deg.C to prepare a paroxetine hydrochloride solution. The solvent to be used in the reaction is pref. one soluble for amines and their salts (e.g. water or a saturated alcohol &lt;=170 deg.C in boiling point; esp. pref. a lower saturated alcohol such as methanol). Thereafter, the paroxetine hydrochloride solution is spray-dried without the need of any concentration, thus obtaining the objective amorphous paroxetine hydrochloride. Production process for the aimed compound under conditions in the absence of water affords anhydrous paroextine hydrochloride.
PURPOSE: To obtain a medicine useful for treating and preventing ulcers and disorders in a gastrointestinal tract and symptoms similar to them, containing a catechol derivative, or its salt or ester. CONSTITUTION: A catechol derivative of the formula (R&lt;1&gt; and R&lt;2&gt; are each H, an acyl which may be substituted, are bonded to form a lower alkylidene, etc.; X is an electronegative substituent group; R&lt;3&gt; is H, a halogen, a substituted alkyl, etc.), its salt or its ester in an amount of 1-100wt.% as an active ingredient is properly mixed with a conventional auxiliary component and pharmaceutically manufactured to give the objective substance. The medicine is administered through intestine or parenterally and preferably an enteric coated tablet is orally administered. In the case of treating the disorder of rectum, a suppository is preferably used. A dose is 1-100mg per adult daily and doses are administered dividedly several times. 1,3,5-Dinitrocatechol is cited as the compound of the formula.
Artificial threads, ribbons, tubes, capsules, pills, or plugs of cellulose or its organic derivatives, or mixtures thereof with polyvinyl compounds, are rendered capable of resorbtion by incorporating therein before, during or after manufacture, oxalic acid, malic acid, an amino acid such as glycocoll or asparaginic acid, or phenylhydrazine hydrochloride.  The substance promoting resorbtion may be added to the spinning solution, or emulsified in the softened cellulose, or incorporated in the formed thread &amp;c. by impregnation.  The strength of the threads may be increased by the incorporation of sulphocyanides and cane sugar.  Bactericidal substances, e.g. propyl benzoate and metal compounds or esters of organic acids may be incorporated; also therapeutically active substances.  Specifications 393,505 and 427,106 are referred to.ALSO:Artificial threads, ribbons, tubes, capsules, pills, or plugs of cellulose or its organic derivatives, or mixtures thereof with polyvinyl compounds, are rendered capable of resorption by incorporating therein, before, during or after manufacture, oxalic acid, malic acid, an amino acid such as glycocoll or asparaginic acid, or phenylhydrazine hydrochloride.  The substance promoting resorption may be added to the spinning solution, or emulsified in the softened cellulose, or incorporated in the formed thread &amp;c. by impregnation.  The strength of the threads may be increased by the incorporation of sulphocyanides and cane sugar. Bactericidal substances, e.g. propyl benzoate and metal compounds or esters of organic acids may be incorporated; also thereapeutically active substances.  Specifications 393,505, [Group IV], and 427,106 are referred to.
Cesarean section is one of the most common surgical operations in obstetrics and gynecology. While the caesarean section rate is 25-40% in developed countries such as the United States, Ireland, England and China, this rate is 48% in Turkey. For this reason, post-cesarean pain and delayed bowel motility are among the common problems due to the surgical intervention. Post-cesarean pain can delay return to normal daily activities and negatively affect the mother\&#39;s psychological health, breastfeeding, and mother-infant bonding. In addition to pain, delayed bowel motility due to changes in the autonomic nervous system is among the most common problems experienced after cesarean section. Appropriate health care provided by medical personnel during the postpartum period can enable the woman to be discharged early. Therefore, non-invasive, low-cost and uncomplicated methods should be preferred to reduce pain in the postoperative period and ensure the first spontaneous passing of gas and early defecation. In the literature review, although there is no study determining the effect of drinking coffee on pain in the postoperative period, there are studies stating that coffee can contribute to early GI motility in the postoperative period after abdominal surgery and shorten the time for passing gas, defecation and discharge. Therefore, this research will be conducted as a randomized controlled experimental study with the aim of minimizing the problems that the mother and the newborn may experience in the postpartum period by eliminating the negative symptoms related to postpartum pain and delayed intestinal motility.
NEW MATERIAL:An amylase inhibitor having inhibitory activity against pancreatic and salivary alpha-amylases without being inactivated with digestive tract proteases, further heat resistance and the following physico-chemical properties. Molecular weight; 15000+ or -1000 (gel filtration method). Properties; properties of proteins. Elementary analysis (%); C, 45.3; H, 6.3; N, 12.1. Melting point ; decomposed at &gt;=220 deg.C. Saccharide content; glycoprotein containing about 6% (phenol sulfuric acid method), etc. USE:A preventive and treating agent for diseases related to saccharide metabolic function such as diabetes, obesity or hyperlipemia, arteriosclerosis, cardiac infarction, etc. PREPARATION:A tuber of a plant of the genus Colocasia is homogenized with a solvent and a soluble ingredient, as necessary, is then subjected to gel filtration, subsequently separated and purified by ion exchange column, hydrophobic column and gel filtration column chromatographies.
A method is for predictive prognosis of a woman&#39;s menopause onset. The method includes accessing the Single Nucleotide Polymorphisms (SNPs) of the woman; processing the woman&#39;s genetic data, to provide a predictive prognosis of menopause onset in relation to the phenotype. The phenotype includes an age group/limit with respect to the predictive prognosis, or indication of a woman&#39;s likely age for menopause onset. The processing includes identifying a predetermined set and subset of SNPs associated with the phenotype. Each of the SNPs the set includes an identifier of SNPs, and is associated with a respective pre-calculated first relevance parameter. A first value of polygenic risk score is calculated based on the first personalized subset of SNPs and respective first pre-calculated relevance parameters. The predictive prognosis of menopause onset relative to each phenotype is determined based on the polygenic risk score.
PURPOSE:To easily produce the hyperchromic glass lens having various kinds of color by coating a solution for an org. hard film contg. a specific hydrolysis condensate as a main component on the surface of the glass lens and then by hardening it followed by dyeing it with a dyeing bath contg. a cationic dye at a specific temperature. CONSTITUTION:The titled glass lens is produced by coating the solution for the org. hard film contg. the hydrolysis condensate shown by formula (1) or (2) as the main component on the surface of the glass lens and by hardening it followed by dyeing the glass lens having the obtd. hardened surface layer thereon using the dyeing bath contg. 0.001-5wt% of the cationic dye at a temp. of preferably 80-120 deg.C. As an alkoxysilane shown by formula (1), one may use methyltrimethoxysilane. As an alkoxysilane shown by formula (2), one may use tetramethoxysilane, etc. If the dying bath contains &lt;=0.001wt% of the dye, the dyeing rate is too late for a practical application. If the dying bath contains &gt;=5wt% of the dye, as the dye easily sticks to the surface to be dyed, and a dependency of the dye concentration about the dyeing rate is almost lost, it makes difficult to freely color by compounding various kinds of dyes for the practical application.
The present invention relates to sweat sensing and the control of sweat sensors for analyzing sweat uptaken by the sweat sensor (600) from a user&#39;s skin. The sweat sensor comprises a data receiving unit (602) configured for receiving a user&#39;s medical data affecting sweat characteristics. A measurement unit (603) comprises various sensors configured for carrying out based on the sweat uptaken by the sweat sensor, a sweat rate (proxy) measurement. A controller (604) selects one or more of the sensors based on the user&#39;s medical data. The present invention uses the insight that the sweat sensor should select the type of sensor depending on the health status of the user. The data receiving unit (602) may be a user interface, a communication interface condition to a database, or a device for measuring the health status of the user directly within the sensor. Measuring the health status can be done, for example, by an SpO 2  sensor, a transcutaneous CO 2  sensor, or an analyte concentration sensor sensing the concentration of the analyte in the uptaken sweat. Since the sweat rate (proxy) sensor is adapted to the medical status of the user, the sweat analysis is more accurate and provides analysis results which are clinically more reliable.
PURPOSE:To obtain the subject new stable derivatives low in irritation to the skin, exhibiting long activity of covering properties, adhesion, a protecting effect, etc., to the skin or hairs and suitable for cosmetics use, etc., by reacting an abiethyl alcohol with a carboxylic acid. CONSTITUTION:An abiethyl alcohol (e.g. tetrahydroabiethyl alcohol) represented by formula R&lt;1&gt; OH (R&lt;1&gt; is groups of formulae I, II, etc.) is reacted with a carboxylic acid (e.g. 2-heptylundecanoic acid) expressed by formula R&lt;2&gt;COOH (R&lt;2&gt; is 7-25C hydrocarbon) in the presence of an acid catalyst such as sulfuric acid in a solvent such as toluence while being heated and refluxed with stirring for 24hr. Generated water is distilled off and, after completion of the reaction, the reaction mixture is washed by using an aqueous solution of sodium bicarbonate, etc. The solvent is distilled off under vacuum and the resultant residue is subsequently subjected to purification by silica gel chromatography, thus obtaining the objective ester derivative (e.g. tetrahydrobiethyl 2-heptylundecanate) represented by formula III.
&lt;P&gt;PROBLEM TO BE SOLVED: To obtain a new bleaching ingredient having high effectiveness and an external preparation for skin for bleaching containing the same.  &lt;P&gt;SOLUTION: The bleaching ingredient comprises at least one kind selected from spiraeoside and kaempferol-7-neohesperidoside. The external preparation for skin for bleaching contains the bleaching ingredient. The bleaching ingredient has inhibitory action on tyrosinase activity, melanin production inhibition, inhibitory action on pigmentation, ameliorating action on human skin color and excellent bleaching effect. The external preparation for skin for bleaching, containing the bleaching ingredient, prevents or ameliorates stains, freckles, drabness and pigmentation such as skin blacking, etc., by suntan.  &lt;P&gt;COPYRIGHT: (C)2005,JPO&amp;NCIPI
PURPOSE:To provide a method for treating hair, capable of easily, simply and effectively improving the quality of hair and reducing the damage to the hair even outside a bath. CONSTITUTION:When hair is treated with steam after or during a time when the hair is coated with a hair-treating agent, (A) a treating agent containing a compound of formula I (R&lt;1&gt; is H, methyl; R&lt;2&gt; is a 1-5C alkyl; (n) is 2-6), e.g. diethyleneglycol monoethyl ether, (B) a treating agent containing a compound of formula II (R&lt;3&gt; is H, a 1-4C alkyl; R&lt;4&gt; is COOH, SO3H), e.g. glycolic acid or lactic acid, and (C) a treating agent containing one or more of a naphthalene sulfonic acid compound, a benzophenone sulfonic acid compound, or an azulene sulfonic acid compound is used as the hair-treating agent. When the treating agent A is used, the generation of the split hair can especially be prevented. When the treating agent B is used, durable flexibility can be imparted to the hair. When the treating agent C is used, durable tension and stiffness can be given to the hair.
Pharmaceutical and veterinary compositions comprise non-toxic, pharmaceutically acceptable, inert diluents or carriers and at least one compound of general formula &lt;FORM:0870469/VI/1&gt; wherein R1 and R2 which may be the same or different represent hydrogen or alkyl radicals optionally substituted by hydroxy or dialkylamino radicals, or R1 and R2, together with the adjacent nitrogen atom form a saturated heterocyclic ring, e.g. a piperidine, morpholine or hexamethyleneimine radical and wherein the ring (A) may optionally bear one or more substituents which may be the same or different selected from lower alkyl, lower alkoxy, lower alkylthio, halogen, nitro, carboxy, carbalkoxy, acyl, alkylaminosulphonyl and acylamino radicals or a non-toxic acid addition salt thereof, the term &#34;lower&#34; denoting radicals containing not more than 6 carbon atoms.  The compositions may be in the form of tablets, capsules, dispersable powders, mixtures with animal foodstuffs and premixes for addition thereto, salt licks and aqueous and oily suspensions for oral and parenteral use.  They may optionally contain &#34;trace elements,&#34; e.g. cobalt, manganese, copper and iodine and known anthelmintic drugs, e.g. piperazine, phenothiazine, hexachloroethane, cyanacethydrazide, copper sulphate or nicotine sulphate.
PURPOSE:To obtain antigen-specific B cell useful for the mass production of antibody by cell fusion technique, economically, by culturing a variety of heterogeneous sensitized B cell in the presence of an antigen-specific proliferation factor derived from T cell. CONSTITUTION:An antigen-specific B cell can be prepared by culturing sensitized B cell in the presence of an antigen-specific proliferation factor originated from T cell. The proliferation factor can be collected from the supernatant liquid obtained e.g. by exposing a mouse to radiation, administering the mouse with about 2X10&lt;8&gt;-2X10&lt;9&gt; thymic cells of the same kind and the usual immunizing amount of antigen, extirpating the splenic cells after 4-10 days, and centrifuging the suspension of the cells. The collected factor can be purified by the affinity chromatography using a complex of a specific antigen and a carrier as an adsorbent. Since antigen-specific B cells can be prepared from the B cells sensitized with crude antigen, the process has an advantage that the crude antigen can be used as a raw material.
A therapeutic composition, useful in muscle regeneration for the treatment of myopathy in metazoan animals, comprise one or more dinitramine compounds of the formula &lt;FORM:1113702/A5-A6/1&gt; wherein each R independently represents H, NH4 or an alkali metal (i.e. Na, K or Li) and at least one R is hydrogen or both R&#39;s are identical, all occurences of alkali metal in a compound being the same, and a pharmaceutically acceptable diluent or carrier.  Preferred nitramines are: N,N1 - dinitroethylenediamine and N,N1 - diammonium - N,N1 - dinitroethylenediamine.  Administration may be by oral or anal introduction, intravascular injection or injection into body cavities or tissues or external application.  The composition may be in the form of tablets, liquid, pellets, powder, chewing gum, gelatin capsules or microcapsules, salve, paste, lotion, or preferably it is mixed with the grain ration or other animal feed compositions.  Feed compositions may contain 0.0001 to 30% by weight of the active ingredient.  The composition may also be formulated as concentrates containing 5-98% by weight of dinitramine compounds.  The composition can also contain other biologically active materials such as vitamins or other dietary supplements, hormones or other growth regulants and/or stimulants.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide an autosomal dominant polycystic kidney disease (ADPKD) 1 type gene and to provide uses thereof.  &lt;P&gt;SOLUTION: The autosomal dominant polycystic kidney disease (ADPKD) is a general genetic disease frequently bringing kidney failures by the development of progressive cyst. The main locus, PKD1 is placed at 16p13.3. A chromosomal translocation is identified in conjunction with ADPKD breaking a gene (PBP) encoding a 14kb transcript in a PKD1 candidate domain. The further mutation of the PBP gene has been discovered in a PKD1 patient, and PBP has been confirmed to be PKD1 gene. The gene is placed adjacently to a vascular sclerosis (2) locus in a genome domain repeated at a nearer position than 16p. This doubled domain encodes three transcripts substantially homologous to PKD1 transcript. The partial sequence analysis of the PKD1 transcript shows that the partial sequence encodes a new protein.  &lt;P&gt;COPYRIGHT: (C)2009,JPO&amp;INPIT
A system for the automated remote monitoring of home health parameter measurement activities to assure outpatient subscriber compliance with prescribed measurement schedule regimen, and to alarm-monitor for off-normal measurements. Typical monitored health parameters include blood pressure, blood glucose level, clotting factor, and the like. The system comprises at least one subscriber remote station which interfaces with a communications link, and a central monitoring station also interfaced with the link and operative to receive and analyze messages transmitted by the remote station. The preferred remote station embodiment transmits measurement outcome messages to the central station each time an interconnected health parameter measurement device generates a signal indicating whether the current measurement is &#34;normal&#34; or &#34;in-alarm&#34;, based on uniquely specified alarm criteria. Central station hardware/software verifies receipt of such signals within each of the subscriber&#39;s uniquely scheduled measurement time windows, and alerts alarm dispatchers to take pre-specified action if a scheduled measurement is forgotten. Dispatchers are also alerted if &#34;in-alarm&#34; measurements occur. Alternative remote station embodiments accept monitoring device signals corresponding to health parameter measured values. One alternative embodiment performs alarm monitoring in the remote station, another performs alarm monitoring at the central station. All embodiments provide subscribers with help-buttons to initiate transmission of alarm messages to the central station in event of emergency. Since the central station is alerted if any scheduled measurement is missed, no immobilizing emergency can go undetected longer than the maximum time between consecutively scheduled measurements.
FIELD: veterinary biotechnology. SUBSTANCE: serum contains antibodies to Fusobacterium necrophorum in a titer being not lower than 1:128 in reaction of agglutination (RA). It is obtained by hyperimmunization of producer bullocks with inactivated formalin leucocydine-exotoxin. The latter is a highly purified protein at 18-20 kDa molecular weight isolated from a production strain Fusobacterium necrophorum &#34;0- 1&#34; VIEV. Hyperimmune serum provides the development of tense passive immunity against necrobacteriosis in cattle and reindeers in case of single injection for about 14 d, not less Therapy efficiency corresponds to 90%. EFFECT: higher efficiency. 2 ex, 1 tbl
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a pulpitis diagnostic system performing accurate and objective diagnosis of pulpitis.  &lt;P&gt;SOLUTION: The pulpitis diagnostic system 300 has an imaging fiber device 200 and a pulpitis diagnostic marker 100. The pulpitis diagnostic marker 100 contains an E-selectin antibody bonded to an outer surface of a liposome including indocyanine green. A silicon tube 420 is attached to a tip end of a fiber of the imaging fiber 210, and the silicon tube 420 is pressed against a side of a tooth affected with pulpitis. The pulpitis diagnostic marker 100 specifically bonds with the pulpitis inflammation site. Fluorescent light of indocyanine green is observed by a monitor 370 to perform accurate and objective diagnosis of pulpitis.  &lt;P&gt;COPYRIGHT: (C)2010,JPO&amp;INPIT
The invention provides an ophthalmic solution with a flavoring agent as a dosing indicator and a method for indicating dosage of an ophthalmic solution. To indicate dosage, a flavoring agent is added to an ophthalmic solution in an amount correlated to the dosage of the ophthalmic solution to be used. The flavoring agent can be a sweet flavoring agent (sweetener), or combinations of a sweetener with a sour flavoring agent or a bitter flavoring agent or mixtures thereof. The flavoring agent may also be natural flavors, natural fruit flavors, artificial flavors, artificial fruit flavors, flavor enhancers and mixtures thereof, which may be combined with a sweetener, a sour flavoring agent, a bitter flavoring agent, and mixtures thereof. The invention may be utilized as a contact lens solution, an eye drop formulation, and a pharmaceutical composition containing at least one active pharmaceutical ingredient for the treatment of eye diseases. The invention also provides to a method of administering a dose of an ophthalmic solution to the person&#39;s eye.